Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Reoxygenation Reverses Hypoxia-related Radioresistance in Head and Neck Cancer Cell Lines.

Tonissi F, Lattanzio L, Astesana V, Cavicchioli F, Ghiglia A, Monteverde M, Vivenza D, Gianello L, Russi E, Merlano M, Lo Nigro C.

Anticancer Res. 2016 May;36(5):2211-5.

PMID:
27127125
2.

E1 detection as prognosticator in human papillomavirus-positive head and neck cancers.

Vivenza D, Lo Nigro C, Denaro N, Fortunato M, Monteverde M, Tonissi F, Lattanzio L, Astesana V, Gloghini A, Volpi CC, Russi E, Merlano MC.

Int J Biol Markers. 2016 Apr-Jun;31(2):0. doi: 10.5301/jbm.5000193. Epub 2016 Mar 22.

PMID:
27040135
3.

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.

Griseri P, Garrone O, Lo Sardo A, Monteverde M, Rusmini M, Tonissi F, Merlano M, Bruzzi P, Lo Nigro C, Ceccherini I.

Oncotarget. 2016 May 3;7(18):26465-79. doi: 10.18632/oncotarget.8417.

4.

Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.

Lattanzio L, Milano G, Monteverde M, Tonissi F, Vivenza D, Merlano M, Lo Nigro C.

Anticancer Drugs. 2016 Jul;27(6):533-9. doi: 10.1097/CAD.0000000000000360.

PMID:
26982238
5.

Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.

Vivenza D, Monteverde M, Lattanzio L, Tonissi F, Astesana V, Denaro N, Comino A, Russi E, Lo Nigro C, Merlano M.

Int J Biol Markers. 2016 May 28;31(2):e183-92. doi: 10.5301/jbm.5000192.

PMID:
26916894
6.

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.

Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC.

World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30. doi: 10.4251/wjgo.v8.i2.222.

7.

The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.

Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O.

Invest New Drugs. 2015 Aug;33(4):801-9. doi: 10.1007/s10637-015-0249-z. Epub 2015 May 7.

PMID:
25947567
8.

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.

Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C.

Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90. doi: 10.1016/j.critrevonc.2015.02.014. Epub 2015 Mar 12. Review.

PMID:
25819749
9.

Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.

Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi E, Milano G, Merlano M, Lo Nigro C.

Invest New Drugs. 2015 Apr;33(2):310-20. doi: 10.1007/s10637-015-0210-1. Epub 2015 Jan 22.

PMID:
25603975
10.

MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.

Lattanzio L, Borgognone M, Mocellini C, Giordano F, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A, Fillini C, Bernucci C, Merlano M, Lo Nigro C.

Int J Biol Markers. 2015 May 26;30(2):e208-16. doi: 10.5301/jbm.5000126.

PMID:
25588856
11.

A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma.

Messa F, Tonissi F, Millo E, Bracco E, Ungari S, Lattanzio L, Merlano M, Damonte G, Lo Nigro C.

Int J Biol Markers. 2014 Mar 24;29(1):e55-61. doi: 10.5301/jbm.5000052.

PMID:
24242294
12.

Role of IL-8 induced angiogenesis in uveal melanoma.

Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M, Lo Nigro C.

Invest New Drugs. 2013 Oct;31(5):1107-14. doi: 10.1007/s10637-013-0005-1. Epub 2013 Aug 4.

PMID:
23912257
13.

Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.

Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano MC, Lo Nigro C.

Anticancer Drugs. 2013 Feb;24(2):120-30. doi: 10.1097/CAD.0b013e328358d1dc.

PMID:
22990129
14.

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.

Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20.

PMID:
22714791
15.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May 17.

PMID:
22608542
16.

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

Urol Oncol. 2013 Aug;31(6):776-86. doi: 10.1016/j.urolonc.2011.03.018. Epub 2011 Jul 27.

PMID:
21795074
17.

Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.

Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

Int J Oncol. 2010 Nov;37(5):1219-28.

PMID:
20878069
18.

Impact of erythropoietin on the effects of irradiation under hypoxia.

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M.

J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5.

PMID:
19499245

Supplemental Content

Loading ...
Support Center